Related references
Note: Only part of the references are listed.Sex Representation in Clinical Trials Associated withFDACancer Drug Approvals Differs Between Solid and Hematologic Malignancies
Shehara Mendis et al.
ONCOLOGIST (2021)
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program
Laurence Albiges et al.
EUROPEAN JOURNAL OF CANCER (2021)
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma
Jens Bedke et al.
EUROPEAN UROLOGY (2021)
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
T. Powles
ANNALS OF ONCOLOGY (2021)
Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS
Stefanie D. Krens et al.
BIOMEDICAL CHROMATOGRAPHY (2020)
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Frede Donskov et al.
EUROPEAN JOURNAL OF CANCER (2020)
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
Wim van Boxtel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Nivolumab plus cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)
L. Cerbone et al.
ANNALS OF ONCOLOGY (2020)
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care
Daniel Castellano et al.
CANCER TREATMENT REVIEWS (2020)
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Nieves Martinez Changa et al.
LANCET ONCOLOGY (2019)
Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma
Vatche Tchekmedyian et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence
Paulo Bergerot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
Steven Lacy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
Steven Lacy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Phase II trial of apatinib in patients with recurrent and/or metastatic adenoid cystic carcinoma of the head and neck: Updated analysis.
Guopei Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
872PPhase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC)
N Agarwal et al.
ANNALS OF ONCOLOGY (2018)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda et al.
CLINICAL CANCER RESEARCH (2016)
Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults
Linh Nguyen et al.
ANTI-CANCER DRUGS (2016)
Analysis of real-world treatment adherence in a cohort of 2,395 patients with metastatic renal cell carcinoma (mRCC).
Jay Margolis et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
Linh Nguyen et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
TAM Receptor Signaling in Immune Homeostasis
Carla V. Rothlin et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice
Aaron P. Mitchell et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
A. B. Suttle et al.
BRITISH JOURNAL OF CANCER (2014)
Exposure-Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma
Masahide Fukudo et al.
CLINICAL PHARMACOKINETICS (2014)
Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer
Ramona Dadu et al.
ONCOLOGIST (2014)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2013)
A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
Karel Eechoute et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
Jennifer Arrondeau et al.
INVESTIGATIONAL NEW DRUGS (2012)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
Brett E. Houk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times
Yanfeng Wang et al.
THERAPEUTIC DRUG MONITORING (2009)
Participation of patients 65 years of age or older in cancer clinical trials
JH Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Increased expression of HGF and c-met in rat small intestine during recovery from methotrexate-induced mucositis
CJ Xian et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
